Navigation Links
Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
Date:9/30/2008

ject to its timely receipt of additional financing and barring any unforeseen changes.

This study has a cell concentration of up to 200 million cells/ml and administers 16 injections per patient, with varying dosing per injection. There are three study groups in the trial, one receiving a total of 800 million cells, one receiving a total of 400 million cells and the third receiving placebo injections. In contrast, previous studies involving MyoCell(R) Therapy had a cell concentration of 50 million cells/ml and administered 32 injections per patient. Animal studies involving MyoCell(R) therapy have suggested increased cell retention, survival and engraftment with the higher concentration of cells and lower number of injections, in part due to lower inflammation response.

"We expect the MARVEL Trial will confirm our current beliefs regarding the safety and efficacy of MyoCell," said Howard J. Leonhardt, CEO and Chief Technology Officer, Bioheart. "Results from our completed Phase I US MYOHEART Trial and Phase II European SEISMIC Trial showed 83-94 percent of the MyoCell(R) treated heart failure patients improved, or did not worsen, in Quality of Life or heart failure class while only 6-17 percent worsened. In comparison, in the SEISMIC Trial control group, 58 percent of the patients that received drugs only improved or did not worsen while 42 percent of such patients worsened.

In October, Bioheart intends to apply for approval to market and reimbursement for MYOCELL(R) Therapy in various countries in Europe for the sickest Class III heart failure patients that continue to deteriorate despite treatment with all currently available therapies applied including drugs, pacers and mechanical assist devices, with no additional therapeutic options.

ABOUT CONGESTIVE HEART FAILURE

Congestive heart failure (CHF), or heart failure, is a condition in which the heart cannot pump enough oxygenated blood to the body's vital organs. People with heart
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
2. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
3. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very pleased ... as its new Chief Executive Officer.  Mark was promoted ... he has overseen the company,s four facilities in ... Rica.  Mr. King joined Tegra Medical in 2012 with 20+ ...
(Date:1/15/2014)... Ill. , Jan. 15, 2014 The Cadence ... Medical Fitness Center by the Medical Fitness Association, a ... to achieve their full potential. The Cadence Fitness & ... the western suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... ATLANTA, Nov. 28, 2011   CardioMEMS, Inc ., an ... commercializing a proprietary wireless sensing and communication technology for ... CEO, Jay Yadav, M.D. , has been recognized ... Endeavor Awards in the Technology Entrepreneur category. The awards ...
... (NYSE Amex: PIP ), a biodefense company ... today that Eric I. Richman, President and Chief Executive ... Healthcare Conference being held November 29-30, 2011.  ... in one-on-one meetings at the conference.Event : , ...
Cached Medicine Technology:TechAmerica and the Technology Association of Georgia Name Dr. Jay Yadav, CardioMEMS Founder & CEO as a Spirit of Endeavor Award Finalist 2TechAmerica and the Technology Association of Georgia Name Dr. Jay Yadav, CardioMEMS Founder & CEO as a Spirit of Endeavor Award Finalist 3PharmAthene to Present at the Piper Jaffray 23rd Annual Healthcare Conference on November 30, 2011 2
(Date:4/15/2014)... mystery and in the process have found a potentially less ... million people a year. The researchers say they now understand the ... in use for more than 50 years even though it ... the microbes it attacks. , A report of the ...
(Date:4/14/2014)... children orphaned by HIV/AIDS in South Africa may provide insight ... issues in other areas of the world, which may have ... to successful interventions. , A report on the global ... to the HIV/AIDS pandemic, which has left 12 million children ...
(Date:4/14/2014)... shows that moderate to severe obstructive sleep apnea is independently associated ... of the 20-year follow-up study show that people with moderate to ... (hazard ratio = 4.2), nearly four times more likely to have ... from cancer (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... youth offenders, the answer to one open-ended question predicted the ... do you think you,ll live?", According to the study, having ... Dr. Alex Piquero said the study found those who don,t ... very high rates and commit more serious offenses, while those ...
(Date:4/14/2014)... fathers hard -- with symptoms increasing dramatically during some of ... Northwestern Medicine study has found. , Depressive symptoms increased on ... fatherhood for these young men, who were around 25 years ... same home as their children. The results of the study ...
Breaking Medicine News(10 mins):Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2
... Jan. 11 (HealthDay News) -- There is little evidence ... relieve the symptoms of osteoarthritis, according to a review ... that involves damage to cartilage and other structures in ... hips. It differs from rheumatoid arthritis, which is an ...
... of researchers at the California Institute of Technology (Caltech) ... The reaction they have come up with should enable ... of organic compounds called nitrogen-containing heterocycles, thus opening up ... natural products ranging from chemotherapeutic compounds to bioactive plant ...
... Denise Mann HealthDay Reporter , WEDNESDAY, Jan. ... their heart race when they are having an irregular ... double their risk of stroke, a new study finds. ... not have a history of atrial fibrillation, more than ...
... During 2010-2011, University of Louisville Health Sciences Center faculty ... $5.7 million in the four regions of Kentucky served ... faculty from UofL provided donated services valued at $5,606,599 ... living and travel expenses in the four regions. These ...
... -- A genetic mutation that causes a rare immune ... been identified by scientists. Symptoms of the disorder ... (cold urticaria), according to the report published online in ... Journal of Medicine . The U.S. National Institutes ...
... HealthDay Reporter , WEDNESDAY, Jan. 11 (HealthDay News) -- ... type 1 diabetes appears to help re-educate rogue immune system ... insulin again. The treatment, which combines a patient,s ... blood, even worked in people with long-standing diabetes who were ...
Cached Medicine News:Health News:Herbal Medicines for Arthritis Not Backed by Evidence 2Health News:Herbal Medicines for Arthritis Not Backed by Evidence 3Health News:Caltech chemists devise chemical reaction that holds promise for new drug development 2Health News:Caltech chemists devise chemical reaction that holds promise for new drug development 3Health News:Even When Silent, Irregular Heartbeat Linked to Stroke Risk 2Health News:UofL centers have economic impact in excess of $5.7 million 2Health News:UofL centers have economic impact in excess of $5.7 million 3Health News:Gene Research Sheds Light on Rare Immune Disease 2Health News:Novel Stem Cell Treatment May Hold Promise for Type 1 Diabetes 2Health News:Novel Stem Cell Treatment May Hold Promise for Type 1 Diabetes 3
Inquire...
Sterilization: sterilized Yes...
Transparent film for easy visual monitoring of samples...
Microporous tape sheets for covering 96-well plates, square-well or flat-bottom blocks.;...
Medicine Products: